ChemoCentryx announces positive overall survival results with CCR2 inhibitor CCX872
ChemoCentryx announced positive OS results from an ongoing Phase Ib clinical trial of the Company's second CCR2 inhibitor - CCX872 - in treatment of locally advanced/metastatic pancreatic cancer. The study demonstrated OS of 29% at 18 months with CCX872 and FOLFIRINOX combination therapy. January 22, 2018